The U.S. Patent and Trademark Office (USPTO) have issued Patent Number 7,157,089 to Nventa Biopharmaceuticals Corporation (TSE: NVN).
The said patent covers compositions of fusion proteins comprised of an influenza antigen fused to a heat shock protein (Hsp), as well as DNA encoding such fusion proteins and their use in immunotherapy.
According to Gregory M. McKee, President and Chief Executive Officer at Nventa:
Source: Nventa Biopharmaceuticals Corporation
"While our focus today is on developing HspE7 for the treatment of serious human papillomavirus-related diseases, this patent strengthens our ability to develop a heat shock fusion protein targeting influenza, likely with the cooperation of a corporate, not-for-profit or government partner.
We are encouraged to have generated promising preclinical data against common and avian flu type using prototypes of Hsp fusion proteins with influenza antigens at a time that we believe there are few companies working on a treatment in this space."
Comment Preview